summary: New treatments are available for early relapsing-remitting multiple sclerosis (MS). The authors studied the effect of a humanised monoclonal antibody, alemtuzumab, in people with early relapsing-remitting MS and found that it significantly reduced the risk of relapse and accumulation of disability compared with interferon beta-1a in a phase 2 trial. They analysed specific and advanced clinical laboratory findings and concluded that improvement in disability after alemtuzumab may result from a specific neuroprotection effect.

authors: Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ.

source: Brain. 2010 Jul 21

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: